At NanoNeurosciences, we’re pioneering advanced peptide-based nanomedicines to tackle ocular and neurological disorders. Our first-in-class therapies are designed to act as receptor agonists that activate critical cell survival and energy pathways, while delivering bioactive molecules directly to affected cells.
Our breakthrough platform technology:
Leveraging our proprietary high-performance supramolecular nanostructures, we precisely target diseased ocular tissues and neural circuits with therapeutic payloads.
This science-driven approach taps into cellular bioenergetics to preserve vision, slow neurodegeneration, and revolutionize treatment for conditions such as Glaucoma, Epilepsy, and Depression.
At NanoNeurosciences, we’re pioneering advanced peptide-based nanomedicines to tackle ocular and neurological disorders. Our first-in-class therapies are designed to act as receptor agonists that activate critical cell survival and energy pathways, while delivering bioactive molecules directly to affected cells.
Our breakthrough platform technology:
Leveraging our proprietary high-performance supramolecular nanostructures, we precisely target diseased ocular tissues and neural circuits with therapeutic payloads.
This science-driven approach taps into cellular bioenergetics to preserve vision, slow
neurodegeneration, and revolutionize treatment for conditions such as Glaucoma, Epilepsy, and
Depression.
At NanoNeurosciences, we’re pushing the boundaries of what’s possible in targeted therapy. Our innovative technology harnesses lipopeptides (LPs) and amphiphilic small molecules (ASMs) to create ultra-stable, next-generation nanocarriers — delivering smarter, more effective treatments. Here’s how:
Precision Targeting & Controlled Release: Our nanocarriers deliver bioactive molecules directly to affected cells, reducing side effects while maximizing therapeutic impact exactly where it’s needed.
Enhanced Stability & Long-lasting Effects: Reinforced with ASMs, these nanostructures stay intact longer — providing sustained, powerful treatment that keeps working over time.
Better Adherence, Better Outcomes: Fewer treatments, lasting results. Our approach promotes improved patient adherence while offering a more cost-effective, convenient solution.
At NanoNeurosciences, we’re redefining what’s possible in eye care. Our first-in-class nanomedicine combines bioenergetic stimulation with cell survival activation — creating a powerful, long-lasting solution for glaucoma treatment.
Our cutting-edge preclinical research focuses on three key breakthroughs:
Building a Powerful Nanomedicine Library: We’re engineering a diverse collection of lipopeptide (LP) sequences designed to form ultra-stable, high-performance nanostructures.
Optimizing for Strength & Stability: By fine-tuning amphiphilic small molecule (ASM) interactions, we enhance nanocarrier stability — ensuring treatments last longer and work more effectively.
Rapid, High-Throughput Screening: Using advanced primary human cellular models, we accelerate molecular screening to identify the most promising, high-impact therapies.
NanoNeurosciences isn’t just keeping up with the future — we’re creating it. Our groundbreaking nanomedicine technology leads the charge in next-generation glaucoma care, offering bold, innovative solutions to protect vision and improve lives.
NanoNeurosciences, Inc.
UF Innovate at Sid Martin Biotech, 12085 Research Dr., Lab 130, Alachua, FL 32615, USA
Copyright © 2025 by NanoNeurosciences, Inc.
